UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
Rivaroxaban Inferior to Warfarin in Prevention of Recurrent Thrombosis in Antiphospholipid Ab Syndrome & Andexanet and Idarucizumab Safe and Effective at Reversing Anticoagulant Effects of DOACs
Comments 0
Login to view comments.
Click here to Login
